
    
      This is a randomized, double-blind, placebo-controlled, study to evaluate the safety and
      tolerability of Nexvax2 preceded by dose titration period in patients with celiac disease
      currently on a gluten-free diet. The study will consist of a Screening Period, a Treatment
      Period, and a Follow-up Period. Eligible subjects will be enrolled in one of three cohorts
      according to whether they are homozygous or not homozygous for both genes coding for
      HLA-DQ2.5.
    
  